glp 1 agonist nash Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Pharmacological Therapeutics: Current Trends for
Description
The LEAN trial with liraglutide and a phase 2 trial of semaglutide in patients with non-alcoholic steatohepatitis (NASH) showed improvements in liver histology and reductions in hepatic inflammation markers
Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al
Hori M, Hasegawa Y, Hayashi Y, Nakagami T, Harada-Shiba M
Liu L, et al
2023), whereas cognitive advantages shown in diabetic individuals indicate a possible preventive effect against Alzheimer's in high-risk groups (Athauda et al
